Loading company…
Boltz develops AI models and tools to support drug discovery from target identification to lead optimization.
Boltz provides an AI platform for drug discovery, with models for protein co-folding, affinity prediction and binder design. Its tools support target screening and lead optimization for biotech firms, pharmaceutical companies and academic institutions. Based in Boston, US, the company raised USD 28.00 mn in Seed funding on December 30, 2025, from Amplify Partners, Andreessen Horowitz, Zetta Ventures, Factorial Capital and Obvious.
2 rounds recorded · latest Private placement (Form D), Oct 2026
Sign in to see 2 rounds.
Sign inSign in to see 5 investors.
Sign inSign in to see 4 more people.
Sign inBoltz PBC has no recorded acquisitions.
Add an acquisitionStill private — no exit on record.
Record an exitNo diversity signals recorded yet for Boltz PBC.
Add diversity data